Lynk Pharmaceuticals Completes Series C2 Financing, Raising a Total of RMB 322 Million in Series C to Advance Innovative Drug Pipeline and Files for Hong Kong IPO

VCBeat has learned that Lingke Pharmaceutical (Hangzhou) Co., Ltd. (“Lingke Pharmaceutical”), an innovative drug R&D company, has officially announced the completion of its C2 round of financing. This round was jointly participated by the Shaoxing Binhai New Area Biopharmaceutical Industry Equity Investment Fund managed by Shengshi Investment, Haibang Investment, and Howbuy Fund of Funds, while existing shareholders Lianxin Capital and Lilly Asia Ventures continued to increase their investments. This is the latest financing secured by the company following its C1 round on May 31, bringing the total amount raised in the Series C round to RMB 322 million to date. Hywin Capital served as the exclusive financial advisor for this round.

Lingke Pharmaceutical, established in 2018, is a leading enterprise dedicated to the research and development of first-in-class (FIC) and best-in-class (BIC) drugs in the fields of autoimmune diseases, inflammation, and oncology. Leveraging the core team’s profound expertise in medicinal chemistry, biology, clinical development, and commercialization, along with an average of over 20 years of experience in new drug R&D, Lingke Pharmaceutical prioritizes innovation and differentiation in its pipeline strategy. The company’s core pipeline focuses on the development of second-generation highly selective and third-generation tissue-specific JAK inhibitors, while also exploring the druggability of novel targets.

Since its inception, Lingke Pharmaceutical has been driven forward by efficient execution. Over the past three months, Phase II clinical trial data for LNK01001 in rheumatoid arthritis, atopic dermatitis, and ankylosing spondylitis have been sequentially released. The results consistently demonstrated significant therapeutic efficacy and a favorable safety profile, fully highlighting the characteristics of rapid onset and potent efficacy associated with this small-molecule JAK1 inhibitor. The company has recently submitted multiple applications for End-of-Phase II/Pre-Phase III meetings. Several pipeline candidates are poised to enter Phase III clinical trials, aiming to benefit more patients as early as possible. Meanwhile, the Phase Ib clinical study of LNK01004 for psoriasis and atopic dermatitis has achieved first-patient enrollment. Early-stage clinical trial data for other pipeline candidates, including LNK01002 and LNK01003, have been positive, and preclinical pipeline development is also advancing rapidly.

Lingke Pharmaceutical’s innovative R&D and clinical development capabilities continue to be validated and strengthened, positioning the company at a critical stage of rapid value realization. According to Frost & Sullivan, the JAK1 inhibitor market alone is projected to reach $30.5 billion by 2030, indicating substantial future growth potential. Leveraging the vast markets in autoimmune diseases and oncology, the company’s future commercialization prospects are highly promising.

Dr. Wan Zhaokui, Chairman and Chief Executive Officer of Lingke Pharmaceutical“We extend our gratitude to the investors in this round—Shaoxing Binhai New Area Biopharmaceutical Industry Equity Investment Fund, Haibang Investment, Howbuy FOF, Lianxin Capital, and Lilly Asia Ventures—for their support and trust. We also thank our Series C1 investors, Tailong Investment and Liandong Investment, for jointly facilitating the successful completion of our Series C financing. Lingke Pharmaceutical is a company focused on autoimmune diseases and oncology, developing first-in-class (FIC) and best-in-class (BIC) innovative drugs with global competitiveness, and is committed to benefiting patients worldwide through differentiated innovative therapies. We are pleased to see that Lingke Pharmaceutical continues to receive support from both existing and new shareholders, even amid the current ‘capital winter’ in the biopharmaceutical sector, which fully demonstrates the capital market’s recognition of our team. Currently, Lingke Pharmaceutical is in a phase of rapid growth. We will further integrate resources from various parties and continue to increase investment in clinical development, R&D teams, and technology platforms, striving to make safer and more effective innovative drugs accessible to more patients as soon as possible. Hywin Capital served as the exclusive financial advisor for this financing round, and we appreciate their professionalism and support.”

Mr. Ding Yameng, Founding Managing Partner and Chief Operating Officer of Haoyue Capital“We are honored to continue assisting Lingke Pharmaceutical in completing this round of financing. The field of autoimmune diseases is characterized by diverse and complex conditions, offering substantial room for indication expansion, with significant unmet clinical needs and differentiated innovation opportunities still present. Lingke Pharmaceutical boasts an innovative pipeline with international competitiveness, which is continuously gaining market validation and recognition. We look forward to seeing the breakthrough potential of Lingke’s several highly differentiated pipelines in subsequent clinical validations, and we believe that under the leadership of a team with strong execution capabilities and a sense of mission, Lingke Pharmaceutical will continue to steadily navigate through cycles, embrace the vast blue-ocean market, and provide better options for patients at an early date.”